Factors suggested to be associated with a response to bevacizumab-based therapy in CRC patients include longer PFS, low LDH levels, KRAS wild-type status, good performance status (PS) and a single site of metastasis [8]. The gene discussed is KRAS; the disease is colorectal carcinoma.